i-base – Reports from CROI 2019
Date:
4/8/19
HIV Treatment Bulletin, published by HIV i-base, includes early reports from the Conference on Retroviruses and Opportunistic Infections (CROI 2019).
Community Resources
China approves albuvirtide: a once-weekly injectable entry inhibitor
Date:
6/29/18
On 6 June 2018, without news from the US FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.
This is a rare example of an HIV treatment not being first approved in either the US or Europe.
Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections
Date:
8/24/18
On 15 August 2018, top-line results from the phase 3 ATLAS study reported that monthly injections with the dual long-acting formulation cabotegravir/rilpivirine were non-inferior as a switch option compared to remaining on triple-drug ART.
The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study randomised 570 HIV positive adults who had been virally suppressed for more than six months on their first or second HIV combination.
Dual bNAb maintains viral suppression for median 21 weeks off-ART
Date:
11/6/18
In the first presentation in a session at R4P2018 looking at using bNAbs for prevention, Pilar Mendoza from the Rockefeller University presented results on the impact of a combination of two antibodies in HIV positive people on ART who then took an analytic treatment interruption (ATI).
bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges
Date:
11/7/18
The R4P2018 conference included a wealth of studies looking at broadly neutralising monoclonal antibody (bNAbs) for HIV prevention.
A selection of these studies reported below shows the complexities of this research which is important given large-scale studies are already ongoing.
Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP
Date:
11/1/18
The properties of long-acting PrEP drugs that reduce the need for daily dosing also presents a new set of challenges if and when people decide to stop.
When LA drugs are used for treatment, this is less of a problem, as HIV positive people will usually be switching to an alternative drug combination.
Dose reduction potential of nanoparticle ARV formulations confirmed in humans
Date:
4/24/17
First in-human trial results of nanoformulations of efavirenz and lopinavir confirmed the potential for a 50% dose reduction to the current standard oral dose of both antiretrovirals.
Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results
Date:
8/10/17
Longer follow-up results from using the first coformulated injectable ART were presented from the phase 2b LATTE study. [1]
Following a lead period that included using oral formulations of cabotegravir and rilpivirine, 286 treatment-naive participants were randomised (2:2:1) to either 8-weekly (8W) or 4-weekly (4W) injections, or to oral cabotegravir plus abacavir/3TC.
Long-acting ART for children is a deferred priority despite achievable dosing
Date:
11/28/17
Optimal doses of long-acting injectable antiretrovirals cabotegravir and rilpivirine were predicted for different weight bands in children and adolescents.
Long-acting injectable antiretrovirals could be future alternatives to oral formulations and might help to address adherence. There is great interest in the potential use of these formulations in the treatment of paediatric HIV.
Question: Is there any research into long-acting treatments?
Date:
1/20/18
Question: I was wondering if there is any hope for a longer term medication. I mean a medication or an injection where you take it a few times a year – or even every few years – and not every day of your life?